We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PTAB Invalidates Second and Third AbbVie Patents on Humira Dosing, Following Coherus’ Challenges
PTAB Invalidates Second and Third AbbVie Patents on Humira Dosing, Following Coherus’ Challenges
The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA approval later this year.